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Rationale & Objective: Chronic kidney disease (CKD) is a leading cause of morbidity and 
mortality worldwide with limited strategies for prevention and treatment. Coffee is a complex 
mixture of chemicals, and consumption is associated with mostly beneficial health outcomes. 
This work aimed to determine the impact of coffee consumption on kidney function. 
Study Design: Genome wide association study (GWAS) and Mendelian randomisation 
(MR). 
Setting & Participants: UK Biobank baseline data were used for a coffee consumption 
GWAS and included 227,666 participants. CKDGen was used for kidney outcomes and 
included 133,814 participants (12,385 cases of CKD) of mostly European ancestry across 
various countries. 
Exposure: Coffee consumption 
Outcomes: Estimated glomerular filtration rate (eGFR), CKD (MDRD eGFR 
<60mL/min/1.73m2) and albuminuria. 
Analytical Approach: GWAS to identify single nucleotide polymorphisms (SNPs) 
associated with coffee consumption in UK Biobank and use of those SNPs in MR analyses of 
coffee consumption and kidney outcomes in CKDGen. 
Results: 2126 SNPs were associated with coffee consumption (p-value <5 x 10-8), 25 of 
which were independent and available in CKDGen. Drinking an extra cup of coffee per day 
conferred a protective effect against CKD (OR 0.84, 95% CI 0.72-0.98, p-value 0.03) and 
albuminuria (OR 0.81, 0.67-0.97, p-value 0.02). An extra cup was also associated with higher 
eGFR (beta 0.022, p-value 1.6 x 10-6) after removal of three SNPs responsible for significant 
heterogeneity (Cochran’s Q p-value 3.5 x 10-15). 
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Limitations: Assays used to measure creatinine and albumin varied between studies that 
contributed data and a sex-specific definition was used for albuminuria rather than KDIGO 
guidelines. 
Conclusions: This study provides evidence of a beneficial effect of coffee on kidney 
function. Given widespread coffee consumption and limited interventions to prevent CKD 
incidence and progression, this could have significant implications for global public health in 
view of the rising burden of CKD worldwide.  
Plain-language summary 
Chronic kidney disease (CKD) is increasing worldwide and represents a major cause of 
death, disability and healthcare expenditure. However, there are few effective options for 
prevention or treatment. 
Coffee is a complex mixture of hundreds of chemical compounds, some of which could have 
beneficial effects on health. Some observational studies link drinking more coffee to a lower 
risk of developing CKD. 
In this Mendelian randomisation study, we used measured variation in genetics, rather than 
self-reported data, to examine the causal effect of coffee on CKD. We showed that among 
coffee consumers, drinking more coffee appeared to protect against CKD. Further work is 
now needed to demonstrate whether a coffee-based intervention is effective for the 





Chronic kidney disease (CKD) is an increasing public health problem with significant 
healthcare costs and morbidity (1). CKD prevalence increased by 27% between 2007 and 
2017, and CKD is now the 12th leading cause of death globally up from 14th a decade ago (2). 
Modelling studies project a continued increase in the burden of CKD and a rise in the number 
of years of life lost from around 26 million annually in 2016 to 52.5 million in 2040 (3). A 
key consequence of CKD is progression to end-stage renal disease (ESRD) requiring renal 
replacement therapy (dialysis or transplantation), which is available to only a fraction of the 
global population (4). CKD is associated with increased risk of cognitive impairment, renal 
bone disease, chronic anaemia and death from sepsis and cardiovascular disease (5–8). The 
definition of CKD includes reduced glomerular filtration rate (GFR) for at least three months 
and/or markers of kidney damage (e.g. albuminuria) (4,9). With no cure for CKD, recent 
focus has been on detection of mild/moderate CKD and prevention of progression to ESRD 
along with strategies to prevent and improve management of hypertension and diabetes in 
those without CKD (10). However, there is currently a lack of effective population level 
strategies for achieving these aims. 
Coffee is a commonly consumed beverage comprising a complex mixture of compounds, 
including caffeine, chlorogenic acid and diterpenes (11). These have a range of in vivo 
properties including anti-inflammatory, antioxidant and antifibrotic effects. Worldwide, over 
two billion cups of coffee are consumed daily (12), so small physiological effects may have 
significant public health implications. Epidemiological studies indicate that coffee may 
protect against liver, neurological, cardiovascular and metabolic diseases, all-cause mortality 
and various cancers (13). For many conditions, the protective effects of coffee appear to be 
dose dependent. However, there may be an upper limit beyond which the benefits of 
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increasing consumption are less pronounced; for example, above 3-5 cups daily for all-cause 
and CVD mortality (14). 
Several epidemiological studies report lower risks of reduced eGFR and CKD among regular 
coffee drinkers (15,16). However, those studies are at high risk of confounding because 
people with CKD risk factors, including high BMI, hypertension, and smoking, tend to drink 
more coffee (17). Reverse causation may also introduce bias if coffee intake reduces due to 
CKD onset and progression. This study attempts to overcome these limitations by, for the 
first time, employing Mendelian randomisation (MR) to investigate the effects of coffee 
consumption on kidney health. MR exploits genetic variations that affect modifiable risk 
factor exposure to estimate a causal association between exposure and outcome (18). 
Previous studies estimate that around 36% to 58% of coffee consumption is heritable (19). 
Genetic variants are assorted randomly during meiosis independently of confounders and are 
not subsequently affected by outcomes. Therefore, MR is less susceptible to confounding and 
reverse causation compared to traditional observational methods (20). 
Methods 
Data for genetic epidemiology of coffee consumption 
The UK Biobank cohort comprises 500,000 participants aged 40-73, recruited between 2006 
and 2013 from across the UK. All participants provided samples for genetic analysis and 
coffee consumption habits were ascertained at baseline from a dietary questionnaire in which 
they were asked how many cups they drank each day and what type of coffee they usually 
drank (instant, ground, decaffeinated or other coffee). All UK Biobank participants gave 
written informed consent and the study was approved by the North West Multi-Centre 
Research Ethics Committee (MREC). A comprehensive description of the UK Biobank 
population and its protocol are available from UK Biobank (21).  
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Creation of a new instrument for the prediction of coffee consumption 
To identify genetic variants associated with coffee consumption, a genome wide association 
study (GWAS) was performed with untransformed daily cups (of any type of coffee) as the 
outcome. Only participants with White British ancestry were included. According to the 
definition of the UK Biobank consortium, White British comprised people self-defined as 
British and with similar genetic ancestry background (22). All single nucleotide 
polymorphisms (SNPs) available as provided by the UK biobank consortium were included. 
To avoid stratification effects (23), participants related to other participants (up to second 
cousin) were excluded. Finally, non-coffee drinkers were excluded to reduce bias from 
reverse causation and participants who abstained due to medical advice, cost or lack of 
exposure to habitual coffee drinking, which left 227,666 participants (approximately 46% of 
total). As sensitivity analyses, we re-ran the coffee GWAS and MR analyses described below 
with non-drinkers included. Analyses were performed using REGSCAN software (24). Age, 
gender, the first 20 genetic principal components, assessment centre, genotyping array and 
genotyping batch were included as covariates. 
Data for genetic epidemiology of kidney function 
GWAS data from the CKDGen Consortium was used for outcomes of eGFR, CKD and 
albuminuria. The CKDGen Consortium has been described elsewhere, including details of 
participant recruitment and genotyping in the individual studies contributing data (25,26). 
The data used in this study are freely available from: http://app.mrbase.org/. Participants were 
diagnosed with CKD where eGFR < 60 mL/min/1.73m2. All except two studies contributing 
data diagnosed CKD from a single measurement of eGFR. GFRs were estimated from serum 
creatinine and the Modification of Diet in Renal Disease study equation (27). The assays for 
measuring creatinine varied between studies and included a modified kinetic Jaffé reaction as 
well as enzymatic photometric and dilutional mass spectrometry-traceable assays (25). 
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Urinary creatinine and albumin were measured from early morning and 24-hour urine 
samples. Methods included immunoturbimetric and nephelometric assays for albumin and 
Jaffé and enzymatic reactions for creatinine (26). Albuminuria was defined as a urinary 
albumin creatinine ratio (UACR) > 17 mg/g (1.92 mg/mmol) in men and > 25 mg/g (2.83 
mg/mmol) in women (26). These sex specific definitions of albuminuria are from a study by 
Warram et al.(28), and differ from the more widely accepted value of ≥ 30 mg/g (in both men 
and women) recommended by KDIGO (Kidney Disease: Improving Global Outcomes) (9). 
They correspond to the 95th percentile UACR values in a group of 218 healthy subjects, and 
are intended to account for men and women on average having differing rates of creatinine 
excretion (29). 
The eGFR GWAS included 48 studies (a mixture of cross-sectional, case-control, cohort and 
randomised controlled studies) and 133,814 participants of various ethnicities. The CKD 
GWAS included a subset of 43 studies and 117,165 participants (12,385 CKD 
cases/outcomes, 104,780 controls/non-cases). In the included studies, mean ages ranged from 
37 (standard deviation [SD] 16) to 81 (SD 9), mean eGFRs from 71.2 (SD 24.1) to 104.8 (SD 
23.8) mL/min, prevalence of CKD (G3-5) from 0.2% to 32.3% and prevalence of diabetes 
and hypertension both from to 0% to 100%. The albuminuria GWAS included 54,450 
participants of European ethnicity. In the included studies, mean ages ranged from 44.9 (7.3) 
to 77.8 (SD 4.8), median UACR from 2.5 to 15.6 mg/g and the prevalence of albuminuria and 
diabetes, respectively, from 2.4% to 25.2% and 1% to 100%. There were approximately 
6,000 cases of albuminuria (the exact number was not reported). The data used in this study 
was summary level data, which was published by the CKDGen consortium in meta-analysed 
form (i.e. after combining the participating individual studies). All the CKDGen studies 
included age and sex as covariates. All participants provided written informed consent and 
local ethical approval was obtained (25).  
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Mendelian randomisation analyses 
MR analyses were first conducted using a two-sample inverse variance weighted (IVW) 
method (30). This method consisted of meta-analysing SNP specific Wald ratios between the 
effect outcome and exposure (i.e. β outcome / β coffee) using a random effects inverse variance 
method that weights each ratio by its standard error while accounting for possible 
heterogeneity in measures (30). For each SNP, β coffee was from the coffee GWAS in UK 
Biobank with units of cups of coffee per day, while β outcome was from CKDGen data and 
units were log odds for CKD and albuminuria and log mL/min/1.73m2 for eGFR.  
To investigate whether any single SNP in the coffee instrument had a disproportionate effect 
on the overall results, IVW analyses were re-run leaving out SNPs one at a time. A key 
assumption of MR is that the SNPs affect the outcome through modification of the exposure 
of interest only with no other causal pathways linking the SNP to the outcome. The existence 
of other pathways is called horizontal pleiotropy (e.g. if the SNPs affected CKD but not 
through coffee). The presence of horizontal pleiotropy may give rise to significant 
heterogeneity. Where significant heterogeneity was detected (inferred using Cochran’s Q), 
the MR-Radial method (31) was used to identify SNPs responsible for heterogeneity (p-value 
= 0.05/number of SNPs) and, in sensitivity analyses, these SNPs were removed and effect 
estimates recalculated. 
Directional pleiotropy occurs when the net effect of horizontal pleiotropy across all SNPs is 
non-zero and introduces bias into the IVW estimates. MR-Egger, weighted median and mode 
are alternative MR methods more robust to directional pleiotropy and were used to calculate 
estimates for comparison with the IVW estimates. MR-Egger allows for some of the SNPs to 
affect the outcome via mechanisms not involving modification of the exposure. The intercept 
from MR-Egger also provides a formal test for directional pleiotropy. Weighted median MR 
assumes that at least 50% of the SNPs are valid. Weighted mode MR groups SNPs into 
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clusters and calculates an estimate based on the cluster with the most SNPs. A recent review 
describes these methods in detail (32). Finally, Steiger-MR was used to test if the SNPs 
explained significantly more variance in exposure than outcome (the opposite may indicate 
reverse causation) (33). The IVW, Egger, weighted median, weighted mode and Steiger-MR 
analyses were performed as implemented in the TwoSampleMR R package (34). The 
datafiles used are provided as supplementary material. 
To investigate confounding, associations of the SNPs with hypertension, diabetes, smoking 
and obesity were extracted from a GWAS involving White British UK Biobank participants 
(35). The effect on the MR estimates of removing SNPs with strong associations with CKD 
risk factors (p-value <1e-5) was investigated in sensitivity analyses. 
Results 
GWAS of coffee consumption in UK Biobank participants 
2126 SNPs were associated with coffee consumption (p<5e-8) in UK Biobank, 574 of which 
were available in the CKDGen GWAS. After removing SNPs that were in linkage 
disequilibrium (r2<0.1) and one unreconciled palindromic SNP, 25 were remaining for use in 
the MR analyses. These SNPs, along with the strength and magnitude of their associations 
with coffee consumption, are shown in table 1. 
Mendelian randomisation analyses 
Table 2 shows causal-effect estimates of coffee on eGFR, CKD and albuminuria from the 
MR analyses. Associations for individual SNPs are presented as supplementary material. 
Figure 1 shows forest plots of the estimates for each outcome using the different MR 
methods. Two forest plots show the coffee-eGFR estimates before and after removing three 
SNPs responsible for significant heterogeneity, and possibly horizontal pleiotropy, as 
described below. Figure 2 shows scatter plots of the SNP-outcome associations against the 
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SNP-coffee associations, allowing visualisation of the causal-effect estimate for each 
individual SNP on eGFR, CKD and albuminuria. Funnel and radial plots are presented as 
supplementary material. 
Coffee and CKD 
In the IVW MR analysis, the OR of CKD for an extra daily cup of coffee was 0.84 (95% CI 
0.72-0.98, p-value 0.03). There was no sign of directional pleiotropy using the MR-Egger test 
(p-value 0.1). In the leave-one-out analysis, estimates ranged from 0.82 (95% CI 0.71-0.95) 
to 0.88 (95% CI 0.77-1.01) suggesting that the observed result was not the effect of a single 
SNP. Estimates were concordant and similar in size in MR-Egger (OR 0.64, 95% CI 0.44-
0.94), weighted median (OR 0.80, 95% CI 0.67-0.96) and mode (OR 0.80, 95% CI 0.66-0.98) 
analyses, supporting a protective effect of coffee against CKD. There was no sign of 
heterogeneity and Steiger-MR indicated the SNPs explained more variance in exposure than 
outcome. 
Coffee and eGFR 
The initial IVW analysis between coffee and eGFR did not provide strong evidence of an 
association (beta 0.015 log mL/min per cups/day, p-value 0.07). In the leave-one-out 
analysis, betas ranged from 0.019 to 0.012. There was evidence of directional pleiotropy 
(MR-Egger intercept p-value 0.04) and horizontal pleiotropy (heterogeneity p-value 3.5e-15). 
After using MR-Radial to remove three outlying SNPs primarily responsible for 
heterogeneity (rs1260326, rs9275576 and rs476828), the IVW association was highly 
significant (beta 0.022, p-value 1.6e-6). This was consistent with estimates (using all SNPs) 
from the weighted median (0.023, 2.8e-5), mode (0.024, 2.4e-4) and MR-Egger (beta 0.053, p-
value 0.01) analyses that are more robust to pleiotropy. Steiger-MR indicated the SNPs 




The causal-effect estimate of coffee consumption on albuminuria was similar in direction and 
magnitude to CKD (0.81, 95% CI 0.67-0.97, p-value 0.02). In the leave-one-out analysis, 
ORs ranged from 0.78 (95% CI 0.63-0.96) to 0.85 (95% CI 0.69-1.05), showing consistency 
in the estimate throughout. None of the estimates from the MR-Egger (OR 0.75, 95% CI 
0.46-1.22), weighted median (OR 0.90, 95% CI 0.69-1.17) or mode analyses (OR 0.83, 95% 
CI 0.60-1.15) were statistically significant, although they were similar in magnitude to the 
IVW estimate, suggesting that this is due to limited power. Analyses with greater power will 
be needed to clarify whether the potential causal relationship is true or due to chance. There 
was no significant horizontal pleiotropy (heterogeneity p-value 0.3) or directional pleiotropy 
(MR-Egger test p-value 0.7). 
Sensitivity analyses 
A GWAS of coffee consumption including drinkers and non-drinkers in UK Biobank found 
44 significant SNPs (p<5e-8) that were also available in CKDGen. Using these SNPs in MR 
analyses (supplementary material) demonstrated IVW associations of an extra daily cup with 
eGFR (beta 0.015 log mL/min, 95% CI 0.003-0.026), CKD (OR 0.81, 95% CI 0.72-0.92) and 
albuminuria (0.85, 95% CI 0.73-0.98), similar to when only drinkers were included. 
Among White British UK Biobank participants, four SNPs were strongly associated with 
hypertension, and removal of these had minimal effect on the estimates (supplementary 
material). 
Discussion 
A GWAS involving 227,666 UK Biobank participants identified 2126 SNPs associated with 
coffee consumption. Using 25 of those SNPs that were independent and available in 
CKDGen, MR analyses showed that increased consumption among regular drinkers appeared 
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to confer a protective effect against CKD (G3-5) and albuminuria, and was associated with 
higher eGFR. The effects were generally similar in magnitude across sensitivity analyses, 
though for albuminuria the effect did not always reach significance at the 5% level, possibly 
due to a smaller sample size. Strengths of this study include use of MR, which largely avoids 
bias from confounding and reverse causality, and large numbers of participants from UK 
Biobank and CKDGen.  
Limitations include potential bias from weak instruments not strongly associated with coffee 
consumption, which would push estimates towards null. An F-statistic (which reflects the 
strength of an instrument) was not calculated because of the lack of an independent 
population. We excluded one unreconciled palindromic SNP, which did not have a significant 
effect on the estimates. The generalisability of the results is uncertain since UK Biobank and 
CKDGen participants were mostly of European ancestry, though this reduced bias from 
population stratification. 
Horizontal pleiotropy may have introduced bias if the SNPs were associated with 
confounders through pathways not involving coffee. No negative control population was 
available to assess this. However, results from MR-Egger, median weighted and mode 
analyses, which are less susceptible to horizontal pleiotropy, were similar to the IVW 
estimates. In addition, excluding SNPs with highly significant associations with CKD causal 
factors had minimal effect on the estimates. Bias from reverse causation would have been 
introduced if CKD was present at baseline and reduced consumption, though the risk of this 
is lower since we excluded non-drinkers and CKD is frequently asymptomatic except in later 
stages. Bias may also have been introduced if the relationships between exposure and 
outcome deviated from linearity, and there was insufficient data available to investigate this. 
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It was not possible to calculate an absolute difference in eGFR for each extra cup of coffee 
(i.e. only the regression coefficient could be calculated). This would have required 
knowledge of baseline eGFRs in non-coffee drinkers and proportions of non-drinkers and 
drinkers of one, two and ≥three cups daily. The CKDGen data release did not include this 
information. 
Further weaknesses relate to ascertainment of coffee consumption in UK Biobank. 
Participants who consumed any type of coffee were included, without information on relative 
consumption of each. Chemical constituents of different coffee types vary (36) and additives 
(e.g. milk or sugar) may have moderated health effects. We also excluded non-drinkers from 
the GWAS of coffee consumption, although this had only a minimal effect (see 
supplementary material). 
Bias may have resulted from case ascertainment in studies participating in CKDGen (i.e. for 
the CKD analysis). In most studies, CKD was identified from a single eGFR. CKDGen 
comprised various study types (cross-sectional, case-control, cohort and randomised studies) 
but did not specify exact numbers of each. Where longitudinal studies were used, it was 
unclear if eGFR was measured and CKD diagnosed at baseline only or at multiple points. 
Variations in eGFR are common and some kidney diseases, such as diabetic nephropathy, 
manifest as hyperfiltration in early stages (37). Guidelines recommend diagnosing CKD 
where eGFR < 60 mL/min/1.73m2 for at least three months and to use CKD-EPI, not MDRD, 
to calculate eGFR (38). As a result, there may have been non-differential misclassification of 
cases and non-cases/controls, which would push estimates towards null. Nevertheless, the 
finding of a robust association with eGFR as a continuous variable suggests that bias related 
to CKD definition was not a significant factor.  
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Insufficient data were available to characterise effect modification by aetiology (e.g. diabetes 
and hypertension) or disease severity or to investigate CKD progression. Diagnostic criteria 
for albuminuria differed from that now recommended by KDIGO (i.e. >17 mg/g in men and 
>25 mg/g, rather than ≥ 30mg/g) (9).  
We were also unable to fully explain the large magnitude of the effect on CKD that was 
comparable the most effective pharmacological therapies in nephrology. This may relate to a 
lifelong exposure to coffee, which is not comparable to shorter-term interventions. In 
addition, ascertainment of coffee consumption through a questionnaire is noisy and, as such, 
the effects of the SNPs on coffee may have been underestimated. This would have led to 
overestimation of the effect sizes but the causal relationships would still be valid. 
This study adds to previous observational studies that provide evidence of a protective effect 
of coffee on kidney health. A cross-sectional study of 2,673 women aged 35-65 (39) reported 
inverse associations between ≥2 cup/day and eGFR < 60 mL/min (OR 0.59, 95% CI 0.37 to 
0.95). Similarly, three other studies reported cross-sectional eGFRs higher among coffee 
drinkers with mean differences (MDs) of 3.20 (0.27-6.13) (40), 2.03 (0.10-3.97) (41) and 
1.61 (0.41-2.81) (42), as summarised in a recent meta-analysis (15). Another cross-sectional 
study reported adjusted MDs showing higher eGFRs in coffee drinkers (MD 5.30, 95% CI 
0.05-10.55) (43). A recent longitudinal study (44) reported lower incidence of CKD with 
greater coffee consumption among 14,209 participants aged 45 to 64 years (HR for <1 cup 
per day, 0.90 [95% CI, 0.82-0.99]; 1-<2 cups per day, 0.90 [95% CI, 0.82-0.99]; 2-<3 cups 
per day, 0.87 [95% CI, 0.77-0.97]; and ≥3 cups per day, 0.84 [95% CI, 0.75-0.94]). However, 
other studies report no association between coffee and CKD (45), and one cross-sectional 
study found lower eGFRs in coffee drinkers, although they were on average 10 years older 
than non-drinkers (46). 
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The active ingredient in coffee responsible for the results of this study is unclear. Non-
caffeine chemical constituents (e.g. chlorogenic acid and diterpenes) reduce inflammation 
and oxidative stress, which are causative in CKD onset and progression (11,47). Caffeine is a 
non-selective antagonist of A1 adenosine receptors (A1AR) on distal afferent arterioles. 
A1AR activation causes vasoconstriction and may lower eGFR (48). Thus, coffee 
consumption may prevent afferent arteriolar constriction or cause vasodilation. Dilation of 
the afferent arteriole alone would increase glomerular capillary hydraulic pressure (Pgc) and 
GFR but would also increase albuminuria and future glomerular damage (49). The observed 
lack of a positive association between coffee and albuminuria is, therefore, reassuring 
because it implies that coffee consumption does not elevate Pgc or provoke glomerular 
damage. Additionally, coffee may protect against CKD risk factors, including diabetes, 
cardiovascular disease and obesity  (13,50). 
This MR analysis suggests a protective role of drinking coffee in maintaining kidney health 
among regular coffee drinkers. The importance of these findings is underlined by modelling 
predictions of growing CKD prevalence in the USA in the next decade, which are most 
sensitive to assumptions in rates of eGFR decline (51). This is in the context of a lack of 
effective interventions to prevent declines in eGFR among populations with and without 
CKD. Next steps should include further MR studies to investigate associations of coffee with 
important risk factors, particularly diabetes and hypertension, which may mediate the effect 
on CKD. A non-linear dose-response at higher levels of consumption should also be 
investigated. This will better define the potential role of coffee in preventing CKD onset and 
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Table 1. A list of 25 SNPs associated with coffee from a GWAS involving UK Biobank participants that were available in the CKDGen GWAS and included 
in the coffee-kidney MR analyses. 
SNP Chr Position Nearest gene  Effect allele Other allele  EAF beta* p-value 
rs2488397 1 197701279 DENND1B C G 0.210 0.040 2.0e-08 
rs1260326 2 27730940 GCKR C T 0.610 0.033 2.4e-08 
rs1877723 4 2846799 ADD1 T C 0.313 -0.040 2.5e-10 
rs1481012 4 89039082 ABCG2 G A 0.111 -0.066 1.5e-12 
rs660550 6 31837277 SLC44A4 A C 0.525 -0.034 8.0e-09 
rs9275576 6 32679326 HLA-DQA2 T C 0.146 0.048 5.5e-09 
rs11766104 7 17192272 AHR T C 0.167 0.043 4.5e-08 
rs4410790 7 17284577 AHR C T 0.640 0.108 6.2e-70 
rs7791070 7 17401027 AHR C T 0.234 -0.076 2.3e-28 
rs17645813 7 17419697 KCCAT333 A G 0.077 -0.073 2.8e-11 
rs6461314 7 17439609 KCCAT333 G A 0.112 0.053 1.2e-08 
rs6949509 7 17519261 LOC101927630 G A 0.435 -0.042 1.5e-12 
rs17706320 7 17551902 LOC101927630 C T 0.342 -0.050 4.7e-16 
rs13233604 7 17593486 LOC101927630 A T 0.172 -0.058 5.0e-12 
rs17145750 7 73026378 MLXIPL T C 0.163 0.050 2.3e-10 
rs17685 7 75616105 POR A G 0.281 0.059 7.5e-20 
rs11855112 15 74133413 TBC1D21 C T 0.129 0.049 3.0e-08 
rs351242 15 74472716 STRA6 A G 0.757 -0.062 9.5e-20 
rs4886593 15 74558078 CCDC33 A T 0.200 -0.052 6.6e-13 
rs4077582 15 74665622 CYP11A1 T C 0.706 0.050 7.9e-15 
rs4128436 15 74935894 CLK3, EDC3 T C 0.081 -0.060 2.1e-08 
rs2472297 15 75027880 CYP1A1 T C 0.272 0.136 2.2e-95 
rs8042558 15 75320433 PPCDC T G 0.235 -0.044 1.3e-10 
25 
 
rs12917120 15 75329091 PPCDC C T 0.665 0.053 2.1e-17 
rs476828 18 57852587 MC4R C T 0.239 0.043 2.0e-10 
 
SNP (single nucleotide polymorphism), EAF (effect allele frequency in the coffee genome wide association study population), *change in cups of coffee/day 
per copy of the effect allele, Chr (chromosome), *none known  
26 
 
Table 2a and 2b. Results from Mendelian randomisation analyses of causal associations of coffee consumption with eGFR, CKD and albuminuria. 
Trait Sample 
size 
Ethnicity MR IVW MR-Egger MR-weighted median MR-weighted mode 
beta† (95% CI)  p beta† (95% CI) p beta† (95% CI) p beta† (95% CI) p 










Ethnicity MR IVW MR-Egger MR-weighted median MR-weighted mode 






Mixed 0.84 (0.72-0.98) 0.03 0.64 (0.44-0.94) 0.03 0.80 (0.67-0.96) 0.01 0.80 (0.66-0.98) 0.04 
Albuminuria§ 54,116‖ European 0.81 (0.67-0.97) 0.02 0.75 (0.46-1.22) 0.3 0.90 (0.69-1.17) 0.4 0.83 (0.60-1.15) 0.3 
Odds ratio (OR), CKD (chronic kidney disease), eGFR (estimated glomerular filtration rate) MR (Mendelian randomisation), IVW (inverse-variance weighted), 
*after removal of three SNPs (rs1260326, rs9275576 and rs476828) that gave rise to significant heterogeneity (p-value 3.5e-15), **per cup of coffee/day †log 




Figure 1. Forest plots showing causal-effect estimates of an extra cup of coffee per day on 
CKD, eGFR and albuminuria. Results are shown for the different methods of mendelian 
randomisation analyses used in this study: inverse variance weighted (IVW), MR-Egger and 
weighted median and mode. The * denotes removal of three SNPs (rs1260326, rs9275576 
and rs476828) that gave rise to significant heterogeneity (p-value of Cochran’s Q 3.5e-15), 
which was possibly the result of horizontal pleiotropy. 
 
Figure 2. Scatter plots in which the SNP-outcome associations are plotted against the SNP-
coffee associations, allowing visualisation of the causal-effect estimate for each individual 
SNP on eGFR, CKD and albuminuria. The * denotes removal of three SNPs (rs1260326, 
rs9275576 and rs476828), shown as red points, that gave rise to significant heterogeneity (p-
value of Cochran’s Q 3.5e-15). Removal of these SNPs improved agreement between the IVW 
regression slope and the MR-Egger, weighted median and mode slopes, which are more 
robust to horizontal pleiotropy. 
 
